The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from <scp>BSBMT</scp>/<scp>UKMF</scp> Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial
British journal of haematology